Good content and good presenters
Tailor your tumor genomic profiling assays using customized #NGS #cancer panels with gene content that fits your needs, including the assessment of new and emerging #biomarkers. In this upcoming webinar, you’ll learn about the new Agilent Technologies SureSelect Cancer Custom panels and how to use the Agilent SureDesign web portal to design your custom panels. Sign up here: https://bit.ly/4apq52y
Director, Software Product Development | Diagnostics and Genomics Group | Agilent Technologies
Learn the power of customization using SureDesign, free probe design tool from Agilent
Tailor your tumor genomic profiling assays using customized #NGS #cancer panels with gene content that fits your needs, including the assessment of new and emerging #biomarkers. In this upcoming webinar, you’ll learn about the new Agilent Technologies SureSelect Cancer Custom panels and how to use the Agilent SureDesign web portal to design your custom panels. Sign up here: https://bit.ly/4apq52y
Join our poster presentation (poster #449) today to learn more about our transcriptomic analysis of treated bone sarcomas, which revealed a unique breakpoint combination in an oncogene and previously unknown gene fusions involving tumor suppressor genes. These findings highlight the importance of RNA-seq to advance research and identify potential biomarkers for sarcomas. https://lnkd.in/eyGqmX44
Student of Pharmacy at Aristotle University of Thessaloniki (AUTH)
So happy and proud to have made my second scientific publication along with my partners Maria Vasileiou, Christina Tsianava, Teodora Mazneva and Kleio Giortsiou at the AccScience Publishing Gene&Protein in Disease Journal (https://lnkd.in/daXprvAM). Through our review paper we aim to shed some light on the role of HIF-1 in cancer and its potential as a therapeutic target.
Want to elevate your NGS analysis quality? OncoKDM provides laboratories with an effective and user-friendly solution to visualize and leverage their QC data. At the sample level, this includes: 📊 Amount of reads 📈 Mean reads 📏 Coverage uniformity 🔍 Exons with coverage greater than 100x 🎯 Mean coverage At the gene level, OncoKDM provides: 🎯 Mean coverage 🔢 Total amount of exons 📈 Mean coverage and uniformity by exons Want to learn more about OncoDNA's QC solutions for laboratories? https://lnkd.in/eN2GiaEb #oncokdm #NGS #qualitycontrol #cancer #precisionmedicine
Genetic Engineering & Biotechnology News featured Bionano's vice president of clinical and scientific affairs, Alex Hastie, in an article on how new technologies, including optical genome mapping (OGM), are advancing how we detect, evaluate and treat cancer due to their ability to identify previously undetected variants and clarify therapeutic options. We’re proud to see such terrific recognition of OGM’s utility in cancer research due to the workflow’s higher resolution and increased sensitivity, which provides a more comprehensive evaluation of structural variations that may impact cancer progression and treatment options. Read the article here: https://lnkd.in/gefhkAES
Maximize #tumor insights with the Agilent Technologies SureSelect Cancer CGP assay, a pan-cancer #NGS panel. Detect key somatic mutations from 679 globally curated genes from cancer samples. Identify de novo gene fusions from RNA. Read the datasheet to learn more: https://bit.ly/3VRWI5D
🔬 Exciting News from Omicsveu! 🧬 Introducing RNAveu, the game-changing system for precise tumor diagnostics. Visualize up to 40 single-copy genes simultaneously with our fully automated, plug-and-play solution. RNAveu's unique two-step hybridization process provides clear, intense signals, enhancing the understanding of tumor heterogeneity and microenvironments. 🌟 Key Features: 1️⃣ Single copy gene visualization up to 40 plex. 2️⃣ Fully automated with NanoVIP®. 3️⃣ Ready-to-use reagents and optimized protocol. Learn More: https://hubs.la/Q02CBZYp0 Transform cancer diagnostics and improve patient outcomes with RNAveu! #CancerDiagnostics #RNAveu #TumorHeterogeneity #BiomarkerDetection #OncologyInnovation #MolecularBiology #NextGenDiagnostics
Comprehensive genomic profiling optimizes cancer testing by covering all clinically relevant genes, including biomarkers that can influence participation in clinical trials. Neo Comprehensive™ – Solid Tumor includes 517 genes by DNA for SNVs and InDels, 59 genes by DNA for CNVs, and 55 genes by RNA for known and novel fusions and splice variants: https://lnkd.in/gPM6f7kv #CGP #ClinicalTrials #SolidTumor https://lnkd.in/g-ccT8EN
🔬 Did you know scientists use CRISPR technology to study how melanoma cells evade drugs? Embark on an exploration of genome editing and CRISPR-Cas9 with our FREE course. Discover how researchers are targeting elusive genes in cancer cells. Our course runs until 9 June 2024, with the flexibility for participants to join at any point during the course. Delivered in an online, self-paced format, this course provides a comprehensive understanding of the groundbreaking applications of CRISPR. Find out more and register here: https://lnkd.in/eEUsyX7i #CRISPR2024 #ScienceEducation #GenomeEditing #EMBL #OnlineCourse
Did you know long term breast cancer endocrine therapy can lead to the development of mutations within the ESR1 gene? Want to learn more? Join us for an educational webinar on: ‘ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance in ER+ Metastatic Breast Cancer’ 👨💻 Who: Christine Hoy and Ronald Vos 📅 When: Wednesday 20th March 14:00-15:00 (GMT) 💻 How: sign up to receive access👀: https://lnkd.in/dSWCKFt4 #webinar #ESR1 #breastcancer